NOVO NORDISK'S RETATRUTIDE: THE NEW HOPE FOR BODY LOSS?

New clinical evidence suggests that Novera Retatrutide, a twin-action treatment from Novo Nordisk, could represent a substantial breakthrough in body control. Beyond many existing drugs, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and the GIP hormone, potentially leading to enhanced